Biomarin Pharmaceutical (WBO:BMRN) Ending Cash Position : €900 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Biomarin Pharmaceutical Ending Cash Position?

Biomarin Pharmaceutical's Ending Cash Position for the quarter that ended in Dec. 2024 was €900 Mil.

Biomarin Pharmaceutical's quarterly Ending Cash Position declined from Jun. 2024 (€903 Mil) to Sep. 2024 (€609 Mil) but then increased from Sep. 2024 (€609 Mil) to Dec. 2024 (€900 Mil).

Biomarin Pharmaceutical's annual Ending Cash Position increased from Dec. 2022 (€684 Mil) to Dec. 2023 (€692 Mil) and increased from Dec. 2023 (€692 Mil) to Dec. 2024 (€900 Mil).

Biomarin Pharmaceutical Ending Cash Position Historical Data

The historical data trend for Biomarin Pharmaceutical's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Ending Cash Position Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

533.61

519.74

683.96

692.45

900.41

Biomarin Pharmaceutical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															692.45	687.24	903.13	608.58	900.41

Biomarin Pharmaceutical Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Biomarin Pharmaceutical's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	721.146	+	179.268
	=	900

Biomarin Pharmaceutical's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	645.053	+	255.361
	=	900

Biomarin Pharmaceutical Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

BMRN:USA BMRN:Mexico 1BMRN:Italy 0HNC:UK BM8:Germany BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.